Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

IV treatment is one of the most traditionalist and wide-spread treatments provided to the 90% of hospitalised patients, yet, recent supply challenges like the Baxter IV fluids crisis have shown ...

Company has B S R & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 1.59 Crore shares outstanding.Automotive Stamp Share Price Today is Rs. 521.20. On previous day, the ...

Rights Jan 28, 2008 Feb 04, 2008 Jan 14, 2008 Rights ratio: 1 share for every 5 held at a price of Rs 1590.0 Rights Nov 26, 1993 Dec 24, 1993 Nov 26, 1993 Rights ratio: 3 share for every 5 held at a ...